| Attribute | Retatrutide | Tirzepatide |
|---|---|---|
| Receptor target | GIP + GLP-1 + glucagon (triple) | GIP + GLP-1 (dual) |
| CAS Number | 2381089-83-2 | 2023788-19-2 |
| Molecular Weight | 4,731.32 g/mol | 4,813.45 g/mol |
| Class | Triple agonist | Dual agonist |
| Research focus | Multi-incretin + glucagon signaling | Dual-incretin signaling |
The added pathway. Retatrutide adds glucagon-receptor agonism on top of the GIP and GLP-1 activity shared with Tirzepatide. Research models use the pair to study the incremental contribution of glucagon-receptor signaling to metabolic endpoints.
Why they are compared. They share the GIP+GLP-1 base, so the comparison isolates the role of the third (glucagon) receptor in next-generation incretin research.
View both compounds
Full mechanism, specifications, and certificates of analysis for each compound.
Frequently asked questions
What is the difference between Retatrutide and Tirzepatide?
Retatrutide is a triple agonist (GIP, GLP-1, and glucagon receptors); Tirzepatide is a dual agonist (GIP and GLP-1). The glucagon-receptor activity is the key distinction. Both are Research Use Only.
Why add glucagon-receptor activity?
In research models the glucagon receptor is studied for its role in energy expenditure and lipid metabolism; Retatrutide lets researchers investigate triple-pathway signaling versus dual.